- Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
- The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
- All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
- Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health
In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension.
“Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” noted Mr. Bunka.
“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added (https://cnw.fm/O7cC0).
It received independent review board approval in what marks a significant milestone for its 2022 R&D program. The approval comes in less than two months after Lexaria announced that it was readying the study protocols for its HYPER-H21-4 study, its fourth recent human clinical study, and its most ambitious one yet (https://cnw.fm/hJ64j).
The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia.
Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively, in a move that is intended to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health.
All the R&D for the 2022 calendar year is fully funded, having raised approximately $15 million in funding over the 2021 calendar year. Lexaria is confident that data from the studies will support the company’s plans to enter regulatory pathways, which, it anticipates, will result in the regulatory approval to use DehydraTECH-CBD for the treatment of hypertension and possibly other types of cardiovascular disease.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Receive Text Alerts from CBDWire: Text “Cannabis” to 21000
For more information please visit https://www.cbdwire.com and or https://CBDWire.News
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
